Results 111 to 120 of about 1,442,267 (182)

Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection [PDF]

open access: yes, 2015
With over 3.5 billion people at risk and approximately 390 million human infections per year, dengue virus (DENV) disease strains health care resources worldwide.
Barrett, Alan D   +9 more
core   +2 more sources

Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. [PDF]

open access: yes, 2018
Human cells express thousands of different surface proteins that can be used for cell classification, or to distinguish healthy and disease conditions.
Adams, Jarrett J   +12 more
core   +1 more source

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies

open access: yesmAbs
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG ...
Wen-Ting K. Tsai   +15 more
doaj   +1 more source

Human immunodeficiency virus neutralizing antibodies and methods of use thereof [APPLICATION] [PDF]

open access: yes, 2014
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of ...
Bjorkman, Pamela J.   +3 more
core  

Combined aptamer and transcriptome sequencing of single cells. [PDF]

open access: yes, 2018
The transcriptome and proteome encode distinct information that is important for characterizing heterogeneous biological systems. We demonstrate a method to simultaneously characterize the transcriptomes and proteomes of single cells at high throughput ...
Abate, Adam R   +3 more
core   +2 more sources

Engineering a novel IgG-like bispecific antibody against enterovirus A71

open access: yesBiochemistry and Biophysics Reports, 2020
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection.
Hsiang-Ching Wang   +7 more
doaj  

The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. [PDF]

open access: yes, 1997
One hypothesis seeking to explain the signaling and biological properties of T cell receptor for antigen (TCR) partial agonists and antagonists is the coreceptor density/kinetic model, which proposes that the pharmacologic behavior of a TCR ligand is ...
Bluestone, JA   +4 more
core  

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy

open access: yesOncoImmunology, 2018
The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor ...
Seandean Lykke Harwood   +16 more
doaj   +1 more source

Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins [PDF]

open access: yes, 2017
Background: Increased expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL is involved in the development and progression of many tumors. We recently reported that the bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 induces apoptosis in lung
Baumann, Bettina   +10 more
core  

An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies

open access: yesAntibodies
Bispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy